{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:50:13Z","timestamp":1793710213066,"version":"4.6.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA045101"],"award-info":[{"award-number":["DA045101"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA045700"],"award-info":[{"award-number":["DA045700"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA016718"],"award-info":[{"award-number":["DA016718"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA040637"],"award-info":[{"award-number":["DA040637"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA035200"],"award-info":[{"award-number":["T32 DA035200"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00213-020-05712-8","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T17:02:57Z","timestamp":1605978177000},"page":"9-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":287,"title":["Cannabidiol: pharmacology and therapeutic targets"],"prefix":"10.1007","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8361-7799","authenticated-orcid":false,"given":"Stevie C.","family":"Britch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Babalonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"5712_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.phrs.2010.05.003","volume":"62","author":"FH Alves","year":"2010","unstructured":"Alves FH, Crestani CC, Gomes FV, Guimaraes FS, Correa FM, Resstel LB (2010) Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res 62:228\u2013236. https:\/\/doi.org\/10.1016\/j.phrs.2010.05.003","journal-title":"Pharmacol Res"},{"key":"5712_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, Mondelli V, McGuire P, Bhattacharyya S (2020) Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237:1121\u20131130. https:\/\/doi.org\/10.1007\/s00213-019-05442-6","journal-title":"Psychopharmacology"},{"key":"5712_CR3","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS (2019) Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology 236:2713\u20132724. https:\/\/doi.org\/10.1007\/s00213-019-05246-8","journal-title":"Psychopharmacology"},{"key":"5712_CR4","doi-asserted-by":"publisher","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019) Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel) 9. https:\/\/doi.org\/10.3390\/antiox9010021","DOI":"10.3390\/antiox9010021"},{"key":"5712_CR5","unstructured":"Azer V et al (2019) Cowen\u2019s collective view of CBD. https:\/\/www.cowen.com\/insights\/cowen-collective-view-of-cbd\/. Accessed 6 Apr 2020"},{"key":"5712_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.11.030","journal-title":"Drug Alcohol Depend"},{"key":"5712_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, de Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schr\u00f6der N, Nardi AE, Mart\u00edn-Santos R, Hallak JEC, Zuardi AW, Crippa JAS (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219\u20131226. https:\/\/doi.org\/10.1038\/npp.2011.6","journal-title":"Neuropsychopharmacology"},{"key":"5712_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774. https:\/\/doi.org\/10.1038\/npp.2009.184","journal-title":"Neuropsychopharmacology"},{"key":"5712_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"IC Bih","year":"2015","unstructured":"Bih IC, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12:699\u2013730. https:\/\/doi.org\/10.1007\/s13311-015-0377-3","journal-title":"Neurotherapeutics"},{"key":"5712_CR10","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.16093","volume":"60","author":"AK Birnbaum","year":"2019","unstructured":"Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE (2019) Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 60:1586\u20131592. https:\/\/doi.org\/10.1111\/epi.16093","journal-title":"Epilepsia"},{"key":"5712_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanu\u0161 L, de Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845\u2013852. https:\/\/doi.org\/10.1038\/sj.bjp.0704327","journal-title":"Br J Pharmacol"},{"key":"5712_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836. https:\/\/doi.org\/10.1007\/s13311-015-0387-1","journal-title":"Neurotherapeutics"},{"key":"5712_CR13","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D\u2019Souza DC, Ranganathan M (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235:1923\u20131932. https:\/\/doi.org\/10.1007\/s00213-018-4885-9","journal-title":"Psychopharmacology"},{"key":"5712_CR14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","volume":"318","author":"MO Bonn-Miller","year":"2017","unstructured":"Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017) Labeling accuracy of cannabidiol extracts sold online. JAMA 318:1708\u20131709. https:\/\/doi.org\/10.1001\/jama.2017.11909","journal-title":"JAMA"},{"key":"5712_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.biopsych.2008.05.011","volume":"64","author":"SJ Borgwardt","year":"2008","unstructured":"Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O'Carroll C, Rubia K, McGuire PK (2008) Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64:966\u2013973. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.011","journal-title":"Biol Psychiatry"},{"key":"5712_CR16","doi-asserted-by":"publisher","unstructured":"Brown JD, Winterstein AG (2019) Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8. https:\/\/doi.org\/10.3390\/jcm8070989","DOI":"10.3390\/jcm8070989"},{"key":"5712_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.nucmedbio.2017.06.003","volume":"52","author":"HG Buchholz","year":"2017","unstructured":"Buchholz HG, Uebbing K, Maus S, Pektor S, Afahaene N, Weyer-Elberich V, Lutz B, Schreckenberger M, Miederer I (2017) Whole-body biodistribution of the cannabinoid type 1 receptor ligand [(18)F]MK-9470 in the rat. Nucl Med Biol 52:63\u201369. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.06.003","journal-title":"Nucl Med Biol"},{"key":"5712_CR18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","volume":"23","author":"S Burstein","year":"2015","unstructured":"Burstein S (2015) Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 23:1377\u20131385. https:\/\/doi.org\/10.1016\/j.bmc.2015.01.059","journal-title":"Bioorg Med Chem"},{"key":"5712_CR19","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar\u00e3es FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond Ser B Biol Sci 367:3364\u20133378. https:\/\/doi.org\/10.1098\/rstb.2011.0389","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"key":"5712_CR20","volume-title":"World Health Organization","author":"Cannabidiol (CBD) Critical Review Report","year":"2018","unstructured":"Cannabidiol (CBD) Critical Review Report (2018) World Health Organization. Expert Committee on Drug Dependence, Geneva"},{"key":"5712_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/00325481.2019.1685298","volume":"132","author":"A Capano","year":"2020","unstructured":"Capano A, Weaver R, Burkman E (2020) Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med 132:56\u201361. https:\/\/doi.org\/10.1080\/00325481.2019.1685298","journal-title":"Postgrad Med"},{"key":"5712_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MH Chagas","year":"2014","unstructured":"Chagas MH et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol (Oxford, England) 28:1088\u20131098. https:\/\/doi.org\/10.1177\/0269881114550355","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, Freeman TP, McGuire P (2020) Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45:1799\u20131806. https:\/\/doi.org\/10.1038\/s41386-020-0667-2","journal-title":"Neuropsychopharmacology"},{"key":"5712_CR24","doi-asserted-by":"publisher","first-page":"e0220025","DOI":"10.1371\/journal.pone.0220025","volume":"14","author":"H Chung","year":"2019","unstructured":"Chung H, Fierro A, Pessoa-Mahana CD (2019) Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: an in silico study. PLoS One 14:e0220025. https:\/\/doi.org\/10.1371\/journal.pone.0220025","journal-title":"PLoS One"},{"key":"5712_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/bf00431988","volume":"66","author":"P Consroe","year":"1979","unstructured":"Consroe P, Carlini EA, Zwicker AP, Lacerda LA (1979) Interaction of cannabidiol and alcohol in humans. Psychopharmacology 66:45\u201350. https:\/\/doi.org\/10.1007\/bf00431988","journal-title":"Psychopharmacology"},{"key":"5712_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Kennedy K, Schram K (1991a) Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 40:517\u2013522. https:\/\/doi.org\/10.1016\/0091-3057(91)90357-8","journal-title":"Pharmacol Biochem Behav"},{"key":"5712_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-g","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991b) Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 40:701\u2013708. https:\/\/doi.org\/10.1016\/0091-3057(91)90386-g","journal-title":"Pharmacol Biochem Behav"},{"key":"5712_CR28","doi-asserted-by":"publisher","unstructured":"Corroon J, MacKay D, Dolphin W (2020) Labeling of cannabidiol products: a public health perspective. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2019.0101","DOI":"10.1089\/can.2019.0101"},{"key":"5712_CR29","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1042\/cs20171288","volume":"131","author":"DG Couch","year":"2017","unstructured":"Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE (2017) Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin Sci (Lond) 131:2611\u20132626. https:\/\/doi.org\/10.1042\/cs20171288","journal-title":"Clin Sci (Lond)"},{"key":"5712_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/ibd\/izz017","volume":"25","author":"DG Couch","year":"2019","unstructured":"Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O\u2019Sullivan SE (2019) Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo\u2014a randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis 25:1006\u20131018","journal-title":"Inflamm Bowel Dis"},{"key":"5712_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA et al (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (Oxford, England) 25:121\u2013130. https:\/\/doi.org\/10.1177\/0269881110379283","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR32","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1089\/can.2019.0024","volume":"0","author":"JAS Crippa","year":"2019","unstructured":"Crippa JAS et al (2019) Oral cannabidiol does not convert to \u03948-THC or \u03949-THC in humans: a pharmacokinetic study in healthy subjects. Cannabis Cannabinoid Res 0:null. https:\/\/doi.org\/10.1089\/can.2019.0024","journal-title":"Cannabis Cannabinoid Res"},{"key":"5712_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000137430","volume":"21","author":"JM Cunha","year":"1980","unstructured":"Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175\u2013185. https:\/\/doi.org\/10.1159\/000137430","journal-title":"Pharmacology"},{"key":"5712_CR34","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L et al (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479\u20131494. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01166.x","journal-title":"Br J Pharmacol"},{"key":"5712_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:791\u2013802. https:\/\/doi.org\/10.1111\/epi.12631","journal-title":"Epilepsia"},{"key":"5712_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/s1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15:270\u2013278. https:\/\/doi.org\/10.1016\/s1474-4422(15)00379-8","journal-title":"Lancet Neurol"},{"key":"5712_CR37","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376:2011\u20132020. https:\/\/doi.org\/10.1056\/NEJMoa1611618","journal-title":"N Engl J Med"},{"key":"5712_CR38","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham K, Zuberi SM, GWPCARE3 Study Group (2018a) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378:1888\u20131897. https:\/\/doi.org\/10.1056\/NEJMoa1714631","journal-title":"N Engl J Med"},{"key":"5712_CR39","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/wnl.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, On behalf of the GWPCARE1 Part A Study Group (2018b) Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 90:e1204\u2013e1211. https:\/\/doi.org\/10.1212\/wnl.0000000000005254","journal-title":"Neurology"},{"key":"5712_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","volume":"167","author":"S Elsaid","year":"2019","unstructured":"Elsaid S, Kloiber S, Le Foll B (2019) Effects of cannabidiol (CBD) in neuropsychiatric disorders: a review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci 167:25\u201375. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.06.005","journal-title":"Prog Mol Biol Transl Sci"},{"key":"5712_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxford, England) 27:19\u201327. https:\/\/doi.org\/10.1177\/0269881112460109","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR42","unstructured":"FDA (2019) Warning letters and test results for cannabidiol-related products"},{"key":"5712_CR43","unstructured":"FDA (2020a) FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease"},{"key":"5712_CR44","unstructured":"FDA (2020b) FDA warns companies illegally selling CBD products to treat medical conditions, opioid addiction"},{"key":"5712_CR45","doi-asserted-by":"publisher","unstructured":"Fitzcharles MA, Clauw DJ, Hauser W (2020) A cautious hope for cannabidiol (CBD) in rheumatology care. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24176","DOI":"10.1002\/acr.24176"},{"key":"5712_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O\u2019Carrol C, Atakan Z, Zuardi AW, McGuire PK (2009) Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66:95\u2013105. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2008.519","journal-title":"Arch Gen Psychiatry"},{"key":"5712_CR47","doi-asserted-by":"publisher","unstructured":"Galaj E, Bi GH, Yang HJ, Xi ZX (2019) Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms. Neuropharmacology:107740. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107740","DOI":"10.1016\/j.neuropharm.2019.107740"},{"key":"5712_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00418-018-1684-7","volume":"150","author":"G Galiazzo","year":"2018","unstructured":"Galiazzo G, Giancola F, Stanzani A, Fracassi F, Bernardini C, Forni M, Pietra M, Chiocchetti R (2018) Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARalpha in the canine gastrointestinal tract. Histochem Cell Biol 150:187\u2013205. https:\/\/doi.org\/10.1007\/s00418-018-1684-7","journal-title":"Histochem Cell Biol"},{"key":"5712_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Galiegue","year":"1995","unstructured":"Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54\u201361","journal-title":"Eur J Biochem"},{"key":"5712_CR50","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA (2015) Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56:1246\u20131251. https:\/\/doi.org\/10.1111\/epi.13060","journal-title":"Epilepsia"},{"key":"5712_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0883073816669450","volume":"32","author":"JS Gofshteyn","year":"2017","unstructured":"Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED (2017) Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol 32:35\u201340. https:\/\/doi.org\/10.1177\/0883073816669450","journal-title":"J Child Neurol"},{"key":"5712_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","volume":"213","author":"FV Gomes","year":"2011","unstructured":"Gomes FV, Resstel LB, Guimaraes FS (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213:465\u2013473. https:\/\/doi.org\/10.1007\/s00213-010-2036-z","journal-title":"Psychopharmacology"},{"key":"5712_CR53","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0269881110389095","volume":"26","author":"FV Gomes","year":"2012","unstructured":"Gomes FV, Reis DG, Alves FH, Correa FM, Guimaraes FS, Resstel LB (2012) Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol (Oxford, England) 26:104\u2013113. https:\/\/doi.org\/10.1177\/0269881110389095","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR54","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.euroneuro.2012.09.007","volume":"23","author":"FV Gomes","year":"2013","unstructured":"Gomes FV, Alves FH, Guimaraes FS, Correa FM, Resstel LB, Crestani CC (2013) Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT(1)A receptor. Eur Neuropsychopharmacol 23:1096\u20131104. https:\/\/doi.org\/10.1016\/j.euroneuro.2012.09.007","journal-title":"Eur Neuropsychopharmacol"},{"key":"5712_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","volume":"22","author":"RA Gray","year":"2020","unstructured":"Gray RA, Whalley BJ (2020) The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord 22:10\u201315. https:\/\/doi.org\/10.1684\/epd.2020.1135","journal-title":"Epileptic Disord"},{"key":"5712_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1300\/J175v03n03_03","volume":"3","author":"GW Guy","year":"2004","unstructured":"Guy GW, Flint ME (2004) A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 3:35\u201377. https:\/\/doi.org\/10.1300\/J175v03n03_03","journal-title":"J Cannabis Ther"},{"key":"5712_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/s1516-44462010000100011","volume":"32","author":"JE Hallak","year":"2010","unstructured":"Hallak JE et al (2010) Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Braz J Psychiatry 32:56\u201361. https:\/\/doi.org\/10.1590\/s1516-44462010000100011","journal-title":"Braz J Psychiatry"},{"key":"5712_CR58","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","volume":"41","author":"M Haney","year":"2016","unstructured":"Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL (2016) Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 41:1974\u20131982. https:\/\/doi.org\/10.1038\/npp.2015.367","journal-title":"Neuropsychopharmacology"},{"key":"5712_CR59","doi-asserted-by":"publisher","first-page":"109637","DOI":"10.1016\/j.pnpbp.2019.109637","volume":"94","author":"A Hartmann","year":"2019","unstructured":"Hartmann A, Lisboa SF, Sonego AB, Coutinho D, Gomes FV, Guimaraes FS (2019) Cannabidiol attenuates aggressive behavior induced by social isolation in mice: involvement of 5-HT1A and CB1 receptors. Prog Neuro-Psychopharmacol Biol Psychiatry 94:109637. https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109637","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5712_CR60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563\u2013583","journal-title":"J Neurosci"},{"key":"5712_CR61","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA (2016) Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 57:1617\u20131624. https:\/\/doi.org\/10.1111\/epi.13499","journal-title":"Epilepsia"},{"key":"5712_CR62","unstructured":"Highlights of Prescribing Information (2018) https:\/\/www.epidiolex.com\/sites\/default\/files\/pdfs\/EPIDIOLEX_Full_Prescribing_Information_04_16_2020.pdf. Accessed 21 May 2020"},{"key":"5712_CR63","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","volume":"113","author":"C Hindocha","year":"2018","unstructured":"Hindocha C et al (2018) Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 113:1696\u20131705. https:\/\/doi.org\/10.1111\/add.14243","journal-title":"Addiction"},{"key":"5712_CR64","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269881117737400","volume":"32","author":"H Hundal","year":"2018","unstructured":"Hundal H et al (2018) The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol (Oxford, England) 32:276\u2013282. https:\/\/doi.org\/10.1177\/0269881117737400","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR65","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176:911\u2013922. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101191","journal-title":"Am J Psychiatry"},{"key":"5712_CR66","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1021\/cn5000524","volume":"5","author":"FA Iannotti","year":"2014","unstructured":"Iannotti FA et al (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5:1131\u20131141. https:\/\/doi.org\/10.1021\/cn5000524","journal-title":"ACS Chem Neurosci"},{"key":"5712_CR67","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/bph.14460","volume":"176","author":"FA Iannotti","year":"2019","unstructured":"Iannotti FA et al (2019) Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol 176:1568\u20131584. https:\/\/doi.org\/10.1111\/bph.14460","journal-title":"Br J Pharmacol"},{"key":"5712_CR68","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/ibd\/izy002","volume":"24","author":"PM Irving","year":"2018","unstructured":"Irving PM et al (2018) A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis 24:714\u2013724. https:\/\/doi.org\/10.1093\/ibd\/izy002","journal-title":"Inflamm Bowel Dis"},{"key":"5712_CR69","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dc16-0650","volume":"39","author":"KA Jadoon","year":"2016","unstructured":"Jadoon KA et al (2016) Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39:1777\u20131786. https:\/\/doi.org\/10.2337\/dc16-0650","journal-title":"Diabetes Care"},{"key":"5712_CR70","doi-asserted-by":"publisher","unstructured":"Jadoon KA, Tan GD, O'Sullivan SE (2017) A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight 2. https:\/\/doi.org\/10.1172\/jci.insight.93760","DOI":"10.1172\/jci.insight.93760"},{"key":"5712_CR71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","volume":"28","author":"IG Karniol","year":"1974","unstructured":"Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 28:172\u2013177. https:\/\/doi.org\/10.1016\/0014-2999(74)90129-0","journal-title":"Eur J Pharmacol"},{"key":"5712_CR72","doi-asserted-by":"publisher","unstructured":"Kossakowski R, Schlicker E, Toczek M, Weresa J, Malinowska B (2019) Cannabidiol affects the Bezold-Jarisch reflex via TRPV1 and 5-HT3 receptors and has peripheral sympathomimetic effects in spontaneously hypertensive and normotensive rats. Front Pharmacol 10(500). https:\/\/doi.org\/10.3389\/fphar.2019.00500","DOI":"10.3389\/fphar.2019.00500"},{"key":"5712_CR73","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"5712_CR74","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neubiorev.2020.01.014","volume":"111","author":"W Lazarini-Lopes","year":"2020","unstructured":"Lazarini-Lopes W, Do Val-da Silva RA, da Silva-Junior RMP, Leite JP, Garcia-Cairasco N (2020) The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: from behavior and mechanisms to clinical insights. Neurosci Biobehav Rev 111:166\u2013182. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.01.014","journal-title":"Neurosci Biobehav Rev"},{"key":"5712_CR75","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/bph.13724","volume":"174","author":"JLC Lee","year":"2017","unstructured":"Lee JLC, Bertoglio LJ, Guimar\u00e3es FS, Stevenson CW (2017) Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol 174:3242\u20133256. https:\/\/doi.org\/10.1111\/bph.13724","journal-title":"Br J Pharmacol"},{"key":"5712_CR76","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. https:\/\/doi.org\/10.1038\/tp.2012.15","journal-title":"Transl Psychiatry"},{"key":"5712_CR77","doi-asserted-by":"publisher","first-page":"112163","DOI":"10.1016\/j.ejmech.2020.112163","volume":"192","author":"H Li","year":"2020","unstructured":"Li H et al (2020) Overview of cannabidiol (CBD) and its analogues: structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer\u2019s disease. Eur J Med Chem 192:112163. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112163","journal-title":"Eur J Med Chem"},{"key":"5712_CR78","doi-asserted-by":"publisher","unstructured":"Liebling JP, Clarkson NJ, Gibbs BW, Yates AS, O'Sullivan SE (2020) An analysis of over-the-counter cannabidiol products in the United Kingdom. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2019.0078","DOI":"10.1089\/can.2019.0078"},{"key":"5712_CR79","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1124\/jpet.106.105247","volume":"318","author":"A Ligresti","year":"2006","unstructured":"Ligresti A et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375\u20131387. https:\/\/doi.org\/10.1124\/jpet.106.105247","journal-title":"J Pharmacol Exp Ther"},{"key":"5712_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2019","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimar\u00e3es FS, Crippa JA (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 41:9\u201314","journal-title":"Braz J Psychiatry"},{"key":"5712_CR81","doi-asserted-by":"publisher","unstructured":"Madden K, Tanco K, Bruera E (2020) Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics 145. https:\/\/doi.org\/10.1542\/peds.2019-3256","DOI":"10.1542\/peds.2019-3256"},{"key":"5712_CR82","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/adm.0000000000000118","volume":"9","author":"AF Manini","year":"2015","unstructured":"Manini AF et al (2015) Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med 9:204\u2013210. https:\/\/doi.org\/10.1097\/adm.0000000000000118","journal-title":"J Addict Med"},{"key":"5712_CR83","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.2174\/138161212802884780","volume":"18","author":"R Martin-Santos","year":"2012","unstructured":"Martin-Santos R et al (2012) Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 18:4966\u20134979. https:\/\/doi.org\/10.2174\/138161212802884780","journal-title":"Curr Pharm Des"},{"key":"5712_CR84","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1471-4159.2007.05073.x","volume":"104","author":"P Massi","year":"2008","unstructured":"Massi P et al (2008) 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104:1091\u20131100. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05073.x","journal-title":"J Neurochem"},{"key":"5712_CR85","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325","journal-title":"Am J Psychiatry"},{"key":"5712_CR86","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737\u2013753. https:\/\/doi.org\/10.1111\/bph.12944","journal-title":"Br J Pharmacol"},{"key":"5712_CR87","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365","journal-title":"Front Pharmacol"},{"key":"5712_CR88","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/ijc.28591","volume":"134","author":"MB Morelli","year":"2014","unstructured":"Morelli MB et al (2014) The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer 134:2534\u20132546. https:\/\/doi.org\/10.1002\/ijc.28591","journal-title":"Int J Cancer"},{"key":"5712_CR89","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38:2433\u20132436. https:\/\/doi.org\/10.1016\/j.addbeh.2013.03.011","journal-title":"Addict Behav"},{"key":"5712_CR90","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","volume":"8","author":"CJA Morgan","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181. https:\/\/doi.org\/10.1038\/s41398-018-0191-x","journal-title":"Transl Psychiatry"},{"key":"5712_CR91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/carcin\/bgs328","volume":"34","author":"M Nabissi","year":"2013","unstructured":"Nabissi M, Morelli MB, Santoni M, Santoni G (2013) Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34:48\u201357. https:\/\/doi.org\/10.1093\/carcin\/bgs328","journal-title":"Carcinogenesis"},{"key":"5712_CR92","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/ijc.29573","volume":"137","author":"M Nabissi","year":"2015","unstructured":"Nabissi M et al (2015) Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer 137:1855\u20131869. https:\/\/doi.org\/10.1002\/ijc.29573","journal-title":"Int J Cancer"},{"key":"5712_CR93","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"T Naftali","year":"2017","unstructured":"Naftali T et al (2017) Low-dose cannabidiol is safe but not effective in the treatment for Crohn\u2019s disease, a randomized controlled trial. Dig Dis Sci 62:1615\u20131620. https:\/\/doi.org\/10.1007\/s10620-017-4540-z","journal-title":"Dig Dis Sci"},{"key":"5712_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/can.2018.0073","volume":"5","author":"JM Nichols","year":"2020","unstructured":"Nichols JM, Kaplan BLF (2020) Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res 5:12\u201331. https:\/\/doi.org\/10.1089\/can.2018.0073","journal-title":"Cannabis Cannabinoid Res"},{"key":"5712_CR95","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","volume":"59","author":"W Notcutt","year":"2004","unstructured":"Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59:440\u2013452. https:\/\/doi.org\/10.1111\/j.1365-2044.2004.03674.x","journal-title":"Anaesthesia"},{"key":"5712_CR96","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/syn.20050","volume":"53","author":"E Nunez","year":"2004","unstructured":"Nunez E et al (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53:208\u2013213. https:\/\/doi.org\/10.1002\/syn.20050","journal-title":"Synapse"},{"key":"5712_CR97","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"A Ohlsson","year":"1986","unstructured":"Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77\u201383. https:\/\/doi.org\/10.1002\/bms.1200130206","journal-title":"Biomed Environ Mass Spectrom"},{"key":"5712_CR98","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1124\/jpet.117.244368","volume":"365","author":"S Petrosino","year":"2018","unstructured":"Petrosino S, Verde R, Vaia M, Allara M, Iuvone T, Di Marzo V (2018) Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacol Exp Ther 365:652\u2013663. https:\/\/doi.org\/10.1124\/jpet.117.244368","journal-title":"J Pharmacol Exp Ther"},{"key":"5712_CR99","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S et al (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133\u2013150. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.041","journal-title":"Pharmacol Ther"},{"key":"5712_CR100","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.forsciint.2018.10.019","volume":"294","author":"JL Poklis","year":"2019","unstructured":"Poklis JL, Mulder HA, Peace MR (2019) The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int 294:e25\u2013e27. https:\/\/doi.org\/10.1016\/j.forsciint.2018.10.019","journal-title":"Forensic Sci Int"},{"key":"5712_CR101","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1523\/jneurosci.0504-08.2008","volume":"28","author":"N Qin","year":"2008","unstructured":"Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231\u20136238. https:\/\/doi.org\/10.1523\/jneurosci.0504-08.2008","journal-title":"J Neurosci"},{"key":"5712_CR102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","volume":"156","author":"LB Resstel","year":"2009","unstructured":"Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS (2009) 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181\u2013188. https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00046.x","journal-title":"Br J Pharmacol"},{"key":"5712_CR103","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037\u20131043. https:\/\/doi.org\/10.1007\/s11064-005-6978-1","journal-title":"Neurochem Res"},{"key":"5712_CR104","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","volume":"303","author":"AG Sartim","year":"2016","unstructured":"Sartim AG, Guimaraes FS, Joca SR (2016) Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex\u2014possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res 303:218\u2013227. https:\/\/doi.org\/10.1016\/j.bbr.2016.01.033","journal-title":"Behav Brain Res"},{"issue":"Suppl 1","key":"5712_CR105","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1590\/s1516-44462012000500008","volume":"34","author":"AR Schier","year":"2012","unstructured":"Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Braz J Psychiatry 34(Suppl 1):S104\u2013S110. https:\/\/doi.org\/10.1590\/s1516-44462012000500008","journal-title":"Braz J Psychiatry"},{"key":"5712_CR106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA et al (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 88:162\u2013171. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.027","journal-title":"Epilepsy Behav"},{"key":"5712_CR107","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1570159x14666160509123955","volume":"15","author":"VP Soares","year":"2017","unstructured":"Soares VP, Campos AC (2017) Evidences for the anti-panic actions of cannabidiol. Curr Neuropharmacol 15:291\u2013299. https:\/\/doi.org\/10.2174\/1570159x14666160509123955","journal-title":"Curr Neuropharmacol"},{"key":"5712_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbr.2010.05.004","volume":"213","author":"VP Soares","year":"2010","unstructured":"Soares VP, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW (2010) Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213:225\u2013229. https:\/\/doi.org\/10.1016\/j.bbr.2010.05.004","journal-title":"Behav Brain Res"},{"key":"5712_CR109","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N et al (2019) A randomised controlled trial of vaporised Delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 269:17\u201335. https:\/\/doi.org\/10.1007\/s00406-019-00978-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5712_CR110","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","volume":"309","author":"AB Sonego","year":"2016","unstructured":"Sonego AB, Gomes FV, Del Bel EA, Guimaraes FS (2016) Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Behav Brain Res 309:22\u201328. https:\/\/doi.org\/10.1016\/j.bbr.2016.04.042","journal-title":"Behav Brain Res"},{"key":"5712_CR111","doi-asserted-by":"publisher","unstructured":"Spindle TR et al (2020a) Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend:107937. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107937","DOI":"10.1016\/j.drugalcdep.2020.107937"},{"key":"5712_CR112","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jat\/bkz080","volume":"44","author":"TR Spindle","year":"2020","unstructured":"Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, Flegel R, Vandrey R (2020b) Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. J Anal Toxicol 44:109\u2013125. https:\/\/doi.org\/10.1093\/jat\/bkz080","journal-title":"J Anal Toxicol"},{"key":"5712_CR113","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86\u201395. https:\/\/doi.org\/10.3109\/03602532.2013.849268","journal-title":"Drug Metab Rev"},{"key":"5712_CR114","doi-asserted-by":"publisher","unstructured":"Sultan SR, O'Sullivan SE, England TJ (2020) The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: a randomised controlled trial. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14225","DOI":"10.1111\/bcp.14225"},{"key":"5712_CR115","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","volume":"87","author":"JP Szaflarski","year":"2018","unstructured":"Szaflarski JP et al (2018) Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav 87:131\u2013136. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.020","journal-title":"Epilepsy Behav"},{"key":"5712_CR116","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053\u20131067. https:\/\/doi.org\/10.1007\/s40263-018-0578-5","journal-title":"CNS Drugs"},{"key":"5712_CR117","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/jcph.1412","volume":"59","author":"L Taylor","year":"2019","unstructured":"Taylor L, Crockett J, Tayo B, Morrison G (2019) A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol 59:1110\u20131119. https:\/\/doi.org\/10.1002\/jcph.1412","journal-title":"J Clin Pharmacol"},{"key":"5712_CR118","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bph.14440","volume":"176","author":"M Tham","year":"2019","unstructured":"Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 176:1455\u20131469. https:\/\/doi.org\/10.1111\/bph.14440","journal-title":"Br J Pharmacol"},{"key":"5712_CR119","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/s0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA et al (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:1085\u20131096. https:\/\/doi.org\/10.1016\/s0140-6736(18)30136-3","journal-title":"Lancet"},{"key":"5712_CR120","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","volume":"15","author":"I Tomida","year":"2006","unstructured":"Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15:349\u2013353. https:\/\/doi.org\/10.1097\/01.ijg.0000212260.04488.60","journal-title":"J Glaucoma"},{"key":"5712_CR121","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","volume":"43","author":"J Turna","year":"2019","unstructured":"Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J (2019) Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res 43:550\u2013563. https:\/\/doi.org\/10.1111\/acer.13964","journal-title":"Alcohol Clin Exp Res"},{"key":"5712_CR122","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M (2019) An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 160:860\u2013869. https:\/\/doi.org\/10.1097\/j.pain.0000000000001464","journal-title":"Pain"},{"key":"5712_CR123","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","volume":"310","author":"MD Van Sickle","year":"2005","unstructured":"Van Sickle MD et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329\u2013332. https:\/\/doi.org\/10.1126\/science.1115740","journal-title":"Science"},{"key":"5712_CR124","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","volume":"75","author":"LR Vilela","year":"2017","unstructured":"Vilela LR et al (2017) Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav 75:29\u201335. https:\/\/doi.org\/10.1016\/j.yebeh.2017.07.014","journal-title":"Epilepsy Behav"},{"key":"5712_CR125","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1191\/0269215503cr581oa","volume":"17","author":"DT Wade","year":"2003","unstructured":"Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17:21\u201329. https:\/\/doi.org\/10.1191\/0269215503cr581oa","journal-title":"Clin Rehabil"},{"key":"5712_CR126","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40263-019-00624-4","volume":"33","author":"JW Wheless","year":"2019","unstructured":"Wheless JW et al (2019) Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs 33:593\u2013604. https:\/\/doi.org\/10.1007\/s40263-019-00624-4","journal-title":"CNS Drugs"},{"key":"5712_CR127","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0039-1695786","volume":"50","author":"A Wiemer-Kruel","year":"2019","unstructured":"Wiemer-Kruel A, Stiller B, Bast T (2019) Cannabidiol interacts significantly with everolimus\u2014report of a patient with tuberous sclerosis complex. Neuropediatrics 50:400\u2013403. https:\/\/doi.org\/10.1055\/s-0039-1695786","journal-title":"Neuropediatrics"},{"key":"5712_CR128","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"DH Xu","year":"2020","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y (2020) The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol 21:390\u2013402. https:\/\/doi.org\/10.2174\/1389201020666191202111534","journal-title":"Curr Pharm Biotechnol"},{"key":"5712_CR129","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.109.162594","volume":"333","author":"KH Yang","year":"2010","unstructured":"Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M (2010) The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther 333:547\u2013554. https:\/\/doi.org\/10.1124\/jpet.109.162594","journal-title":"J Pharmacol Exp Ther"},{"key":"5712_CR130","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.bbmt.2015.05.018","volume":"21","author":"M Yeshurun","year":"2015","unstructured":"Yeshurun M et al (2015) Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant 21:1770\u20131775. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"5712_CR131","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","volume":"159","author":"TV Zanelati","year":"2010","unstructured":"Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159:122\u2013128. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00521.x","journal-title":"Br J Pharmacol"},{"key":"5712_CR132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"5712_CR133","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimar\u00e3es FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82\u201388. https:\/\/doi.org\/10.1177\/026988119300700112","journal-title":"J Psychopharmacol"},{"key":"5712_CR134","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW et al (2009) Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol (Oxford, England) 23:979\u2013983. https:\/\/doi.org\/10.1177\/0269881108096519","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5712_CR135","doi-asserted-by":"publisher","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, Crippa JAS (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8. https:\/\/doi.org\/10.3389\/fphar.2017.00259","DOI":"10.3389\/fphar.2017.00259"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-020-05712-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:39:52Z","timestamp":1610105992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-020-05712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5712"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05712-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}